Burning Rock Biotech, which provides DNA sequencing-based cancer therapy selection tests in China, raised $223 million by offering 13.5 million ADSs at $16.50, above the range of $13.50 to $15.50. Insiders had indicated on $79 million of the IPO (35% of the deal)...read more
Burning Rock Biotech, which provides DNA sequencing-based cancer therapy selection tests in China, announced terms for its IPO on Friday. The company plans to raise an additional $25 million in a concurrent private placement to Lake Bleu Capital. The...read more
An insurance platform and a medical device company went public this past week, both of which upsized their deals and priced above the range. Two SPACs also went public. The IPO market is continuing to open up, and an uptick in filings is setting the stage for a...read more
US IPO Weekly Recap: Vroom soars in another 8 IPO week
Eight IPOs and one SPAC entered the public markets this past week led by Vroom (VRM), which popped 118% in ...read more
Chinese cancer test provider Burning Rock Biotech prices US IPO at $16.50, above the range
Burning Rock Biotech, which provides DNA sequencing-based cancer therapy selection tests in China, raised $223 million by offering 13.5 million ADSs at $16.50, above the range of $13.50 to $15.50. Insiders had indicated on $79 million of the IPO (35% of the deal)...read more
Chinese cancer test provider Burning Rock Biotech sets terms for $196 million US IPO
Burning Rock Biotech, which provides DNA sequencing-based cancer therapy selection tests in China, announced terms for its IPO on Friday. The company plans to raise an additional $25 million in a concurrent private placement to Lake Bleu Capital. The...read more
US IPO Weekly Recap: The IPO market picks up before Memorial Day
An insurance platform and a medical device company went public this past week, both of which upsized their deals and priced above the range. Two SPACs also went public. The IPO market is continuing to open up, and an uptick in filings is setting the stage for a...read more